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Summary
Objective: Nitric oxide (NO°) is a free molecule produced by NO synthases which acts as a mediator in inflammatory processes. NO° can
react with thiol groups of proteins to produce nitrosothiols. Increased concentrations of these bioactive compounds have been found in sera
and synovial fluids from patients with osteoarthritis (OA). The aim of this study was to assess the ability of human osteoarthritic chondrocytes
to synthesize nitrosothiols and to compare the in vitro effects of rhein, cortisol and diclofenac on nitrosothiol and nitrite production.
Methods: Osteoarthritic chondrocytes were incubated for 24 h with 1 ng/ml of recombinant human interleukin-1 (IL-1) in the presence or
absence of rhein (1.3×10−5 M, 6.5×10−6 M, or 1.3×10−6 M), cortisol (10−5 M) or diclofenac (10−5 M or 10−6 M). Nitrite levels were
measured in cell supernatants by the Griess method; nitrosothiol levels were determined in supernatants and cellular lysates by fluorimetry.
Results: At the basal level, nitrosothiols represented 80% of the total of nitrite and nitrosothiol production. After IL-1 stimulation, NO°
production was highly increased in the supernatants (45-fold increase in nitrite, 60-fold increase in nitrosothiols) as well as in cell lysates
(35-fold increase in nitrosothiols). Rhein caused a dose-dependent decrease in nitrosothiol and nitrite production. In comparison, diclofenac
(10−5 M) moderately decreased nitrite and nitrosothiol levels in the supernatants but had no effect on lysate nitrosothiol. Cortisol had no
significant effect on NO° production.
Conclusions: The IL-1 stimulation increased nitrosothiol production by osteoarthritic chondrocytes. These results demonstrate the need to
measure nitrosothiol as well as nitrite production. Rhein inhibited the IL-1 induced NO° production, and may be a suitable treatment for
osteoarthritis. © 2001 OsteoArthritis Research Society International
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Nitric oxide (NO°) is a free radical generated enzymatically
from L-arginine by NO synthase (NOS) isoenzymes.1
Several studies have reported that the levels of NO°
breakdown products (nitrite and nitrate) are higher in syn-
ovial fluids than in serum from patients with rheumatoid
arthritis or osteoarthritis (OA), suggesting that NO° may be
a local mediator of inflammation in both diseases.2–3 NO°
contributes to inflammatory and arthritic tissue destruction
by inhibition of cartilage macromolecule synthesis, such as
collagen type II and proteoglycan,4 and by enhancing
matrix metalloproteases (MMPs).5 Furthermore, NO° leads
to inhibition of DNA replication6 and protein synthesis7 and
induces apoptosis.8–9 Chondrocytes appear to be a signifi-
cant source of NO° in OA articular sites. In contrast to
normal cartilage, OA-affected cartilage can spontaneously
release NO° in sufficient quantities to induce cartilage
damage in ex-vivo conditions.10 OA cartilage over-
expresses NOS, especially at the cartilage surface,
but NOS is not detectable in normal cartilage.11 In the
presence of pro-inflammatory cytokines such as IL-1,12
TNF-,13 IL-1714 or IL-18,15 chondrocytes over-produce1NO°. The inducible OA-affected NOS has similar molecular
weight and antibody cross-reactivity as the neuronal NOS
isoform.16
NO° is a widespread mediator with a short half-life.17 It
can be easily converted into a variety of related molecules
such as peroxynitrite and nitrite, or it interacts with sulfhy-
dryl groups of proteins to form nitrosothiols. Nitrosothiols
can act as physiological mediators since they have similar
biological properties to NO° and they can play a role in
the secretion and the storage of NO°. Nitrosothiols
were recently identified in certain tissues in micromolar
concentrations.18 Moreover, we have previously reported
increased concentrations of nitrosoproteins in sera and
synovial fluids from patients with rheumatoid arthritis and,
to a lesser extent, with OA.19 These molecules are an
important part of bioactive NO° compounds. Measurement
of nitrosothiol concentrations could be more important than
the measurement of nitrite levels.
Rhein is the active metabolite form of diacerein, a new
anti-rheumatic drug. This low molecular weight heterocyclic
anthracenic compound has beneficial effects in animal
models of OA.20,21 Nguyen et al.22 have shown clinical
benefits of rhein in the treatment of OA of the hip. The
mechanism of action of this molecule is different from that
of non-steroidal anti-inflammatory drugs. Rhein is known to
inhibit the effects of IL-1 but has no effect on phospho-
lipase A2 or on cyclooxygenase.23,24 Recently, Pelletier
et al.25 have shown an inhibitory effect of diacerein and
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SOURCES
Ham’s F12 medium and phosphate-buffered saline
(PBS) were obtained from Gibco (Grand Island, U.S.A.),
and fetal calf serum (FCS) was obtained from BioWhittaker
(Verviers, Belgium). Clostridia type I collagenase, porcine
trypsin, sodium nitrite, sulfanilamide, N-1-naphtylethylene-
diamide dihydrochloride, 2,3-diaminonaphtalene (DAN),
glutathione, NH4-sulfamate, HgCl2, cortisol, and diclofenac
were obtained from Sigma (St Louis, MO, U.S.A.). Human
recombinant interleukin-1 (IL-1) was from Genzyme
(Boston, MA, U.S.A.). Rhein was a generous gift of Negma
laboratories.SPECIMEN SELECTION
Human cartilage specimens were isolated from surgical
samples obtained during hip surgery on patients with OA.
Ten patients (nine F/one M, aged 78±10 years, mean±S.D.)
were selected for this study. Diagnosis was made
according to the American College of Rheumatology
27criteria.CARTILAGE DISSECTION AND CHONDROCYTE CULTURE
Chondrocytes were obtained as previously described.28
Briefly, cartilages were carefully dissected from the under-
lying bone. Small fragments of cartilage were enzymatically
digested using trypsin and collagenase. Cells were sus-
pended in Ham’s F12 medium containing 10% FCS, netil-
micin, ceftazidin, vancomycin and amphotericin B, and
were plated at 1.5×106 cells in 75 cm2 culture flasks. Cells
were cultured until confluence in an atmosphere containing
5% CO2. The medium was changed every 3 days. When
confluence was attained, a passage was carried out, using
trypsin. Cells (7×104) were suspended in 1 ml of Ham’s
F12 with 10% FCS and placed in 4 cm2 12-well plates
at 37°C (5% CO2). All experiments were performed on
confluent cultures at first passage.CHONDROCYTE TREATMENT
The growth medium of the chondrocyte cultures was
replaced by fresh medium without FCS. To determine the
NO° production over time, cells were incubated for 6, 18 or
24 h either with or without IL-1 (1 ng/ml). To determine
the effect of rhein, diclofenac and cortisol, cells were
co-incubated for 24 h with (1) no additives, (2) IL-1 (1 ng/
ml) and rhein (1.3×10−5 M, 6.5×10−6 M or 1.3×10−6 M),
(3) IL-1 (1 ng/ml) and diclofenac (10−5 M), (4) IL-1 (1 ng/
ml) and cortisol (10−5 M). In other experiments cells were
first stimulated by IL-1 (1 ng/ml) for 6 h then drugs
were introduced into the medium for the last 18 h.NITROSOTHIOL MEASUREMENTS
Nitrosothiol levels were determined by a fluorimetric
method as described by Marzinzig et al.29 For intracellular
nitrosothiol determination, cells were lysed by incubation
with 20 l 1 M NaOH for 10 min. Basic pH did not influence
the NO liberation from nitrosothiols. Lysates were
neutralized with 1 M HCl. The supernatant or lysate (50 l)
was diluted in 50 l distilled water. NH4-sulfamate (50 l of
0.1 mM) was added to trap nitrite. The mixture was incu-
bated for 10 min, 50 l of reaction mixture (one part 1.1 mM
HgCl2 and four parts 0.05 mg/ml DAN in 0.62 M HCl) was
added, and the complete mixture was incubated for
10 min at room temperature in the dark, then, 2.8 M
NaOH (20 l) was added. Acid pH liberated NO from
nitrosothiols. The fluorescence intensity was measured in
a 96-well microtiter plate (Pharmacia) at excitation/
emission wavelengths of 360 nm and 450 nm, respect-
ively. Nitrosothiol stocks for generating standard curves
were prepared as follows: 50 l of glutathione at various
concentrations (0.15 to 10.0 M in 1 m HCl) was incu-
bated with 50 l NaNO2 (10 mol/l) at room temperature
in the dark for 2 h. The reaction mixture was incubated
with 50 l NH4-sulfamate (100 mol/l). Total cell protein
was assayed according to Lowry et al.30 with bovine
serum albumin as a standard. Results are expressed as
nmol/mg of cellular protein.NITRITE MEASUREMENTS
Nitrite was measured in cultured cell supernatants
by diazotization reaction of Griess with a microplate
adaptation.31 Briefly, 100 l of culture supernatant was
incubated with 100 l of 1% sulfanilamide, 0.1% N-1-
naphthylethylenediamine dichloride in 25% H3PO4 at room
temperature for 10 min. Optical densities were measured at
570 nm using a Dynatech MR 5000 microplate reader
(Dynex Technology S.A., France). Background levels of
nitrite were determined in cell-free Ham’s F12 medium with
or without additives and were subtracted from the total
amount of nitrite formed. The nitrite concentration was
calculated from a NaNO2 standard curve. The detection
limit for nitrite was 0.1 mol/l. Results are expressed as
nmol/mg of cellular protein.CELL VIABILITY
Cell viability was calculated from the release of lactate
dehydrogenase (LDH) into supernatants. For this determi-
nation, culture supernatants were removed at the end of
incubation and the cells were lysed with 200 l of 1% Triton
X-100. The LDH activities of supernatants and lysed cells
were calculated using the following formula: LDH release
(%)=100×supernatant LDH/(supernatant LDH+cellular
LDH). Cellular viability was calculated as follows: 100−LDH
release (%).STATISTICAL ANALYSIS
Results are expressed as mean±S.E.M. of triplicate
measurements. Comparisons were made using the Mann–
Whitney U-test. Differences with P-values of less than 0.05
were considered significant.rhein on nitrite production by IL-1 stimulated chondro-
cytes, and a partial inhibition of the expression of the
inducible NO synthase. Yaron et al. showed that diacerein
and rhein increased IL-1ra levels in cartilage culture
media.26
The aim of this study was to assess for the first time the
ability of human osteoarthritic chondrocytes to synthesize
nitrosothiols and to compare the effects of rhein, diclofenac
and cortisol on the production of nitrosothiols.
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NO° production by cultured osteoarthritic chondrocytes after 24 h
of IL-1 stimulation (1 ng/ml)
Before IL-1 stimulation
(nmol/mg of protein)
After IL-1 stimulation
(nmol/mg of protein)
Nitrite
(supernatant) 1.56±2.42 92.34±80.1
Nitrosothiol
(supernatant) 3.67±0.85 168±74.9
Nitrosothiol
(lysate) 2.96±0.93 101.3±85.2
Results are expressed as mean±1 S.D. of five patients.0 30
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Fig. 1. NO° production by OA chondrocytes over time. Cells were
stimulated by IL-1 (1 ng/ml). Nitrite levels were determined in
cellular supernatants and nitrosothiol levels were measured in
supernatants and cell lysates, as described in Materials and
methods, at 0, 6, 18 and 24 h. Results are expressed as mean±
1 S.D.; results are representative of three independent experiments.NITROSOTHIOL AND NITRITE PRODUCTION BY OA CHONDROCYTES
Table I shows the levels of nitrosothiols and nitrite before
and after 24 h of stimulation by IL-1 (1 ng/ml). At the basal
level, nitrosothiols represented 80% of the total nitrite and
nitrosothiol production by OA chondrocytes. After 24 h of0
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IL-1 + rhein 10–5 M
IL-1 + rhein 10–6 M
IL-1 + rhein 5 × 10–6 MFig. 2. Effects of co-incubation of OA chondrocytes with IL-1 and
rhein, diclofenac or cortisol on production of (A) nitrite in superna-
tants, (B) nitrosothiol in supernatants, (C) nitrosothiol in cellular
lysates. Cells were incubated with IL-1 (1 ng/ml) for 24 h with or
without rhein, diclofenac or cortisol at the indicated final concen-
tration. Results are expressed as mean percentage±1 S.E.M.
*P<0.05, **P<0.01, ***P<0.001 vs IL-1 treated cells.stimulation, NO° production was highly increased relative
to the untreated cells in the supernatants and in the lysates:
4 D. Borderie et al.: Inhibition of nitrosothiol productionabout 45 times for nitrosothiols in the supernatants, about
60 times for nitrite in the supernatants and about 35 times
for nitrosothiols in the lysates. Time-comparison experi-
ments revealed an increasing production of nitrosothiols in
both basal and stimulated cells (Fig. 1).Table II
Cell viability after treatment by rhein, diclofenac and cortisol
Treatment Viability
%
Control 100
Rhein (1.3×10−4 M) 75±8
Rhein (1.3×10−5 M) 94±3
Rhein (5×10−6 M) 96±3
Rhein (1.3×10−6 M) 95±4
Cortisol 10−5 M 94±3
Diclofenac 10−5 M 96±4
Diclofenac 10−6 M 98±2EFFECTS OF TIME ON THE ASSOCIATION OF IL-1 AND THE DRUGS
To determine the influence of time on the association of
IL-1 with the drugs, cells were first treated with IL-1
alone, then drugs were introduced in the growth medium for
the last 18 h. As indicated in Fig. 3, cortisol (10−5 M) and
diclofenac (10−5 M) had no significant effect on the NO°
production. Only the highest concentrations of rhein
decreased nitrosothiol production in the supernatants
(about 50% for 10−5 M rhein and about 40% for
6.5×10−6 M rhein). 10−5 M rhein induced a 40% reduction
in nitrite production in the cell supernatants, compared with
a reduction of 30% at a dose of 6.5×10−6 M. Rhein had
only a moderate effect on the level of nitrosothiols in the cell
lysates (about 15% reduction for 10−5 M rhein).0
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**Fig. 3. Effects of incubation of OA chondrocytes with IL-1 for 6 h,
followed by co-incubation of IL-1 with rhein, diclofenac and cortisol
for 18 h on production of: (A) nitrite in supernatants, (B) nitrosothiol
in supernatants, (C) nitrosothiol in cellular lysates. Cells were
incubated with IL-1 (1 ng/ml) for 6 h alone, then with or without
rhein, diclofenac or cortisol at the indicated final concentration.
Results are expressed as mean percentage±1 S.E.M. *P<0.05,
**P<0.01, ***P<0.001 vs IL-1 treated cells.EFFECTS OF DRUGS ON NO° PRODUCTION AFTER 24 H
The effects of rhein, diclofenac and cortisol on nitro-
sothiol production were studied on OA chondrocytes (N=5)
treated for 24 h with a combination of IL-1 (1 ng/ml) and
one of these drugs. As shown in Fig. 2, rhein induced a
dose-dependent decrease in nitrosothiol and nitrite produc-
tion. The maximal effect was obtained at the concentration
of the 1.3×10−5 mol/l. At this concentration, there was a
78% inhibition of nitrosothiols in the lysates and nitrite in the
supernatants, and a 68% inhibition of nitrosothiols in the
supernatants. A cytopathic effect was observed when
the concentration was higher (1.3×10−4 M) (Table II). In
comparison, diclofenac (10−5 M) moderately decreased
the production of nitrite and nitrosothiols in the super-
natants (about 20%) and had no significant effect on
nitrosothiols in the lysates. Cortisol (10−5 M) had no
significant effect on NO° production.
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This study is the first to assess the capacity of human
cells, especially chondrocytes, to produce nitrosothiols, a
bioactive metabolite of NO°. At the basal level, nitrosothiols
make up a significant fraction of total NO° metabolites
(more than double the level of nitrite in the supernatant).
Nitrosothiols are increased after IL-1 induction to the
same extent as nitrite. Therefore, a measure of nitro-
sothiols instead of nitrite in the supernatants and cell
lysates separately could be important when studying NOS
activity. In articular sites under IL-1 stimulation, chondro-
cytes are probably at least partially the source of nitro-
sothiols found in synovial fluids from OA patients.19 It would
be expected that some part of NO° generated from cells
can form adducts with cellular SH-compounds, such as
glutathione, to form nitrosothiols.32 This relatively stable
complex may diffuse to remote sites and release bioactive
NO. Moreover, nitrosothiols themselves have biological
properties similar to NO°33 and constitute a real and
terminal mobilizable pool. Nitrosothiols have been impli-
cated in intracellular signaling processes and are respon-
sible for the nitrosylation and the activation of p21ras.34,35
Nitrosothiols may also be toxic to cells by disrupting
protein structure or interfering with the catalytic activity of
enzymes.36,37
OA treatment is based currently on analgesics and
non-steroidal anti-inflammatory drugs (NSAIDs). However
these drugs do not slow down the progression of OA.
Recent findings have shown a beneficial effect of inhibiting
NO° production in vivo in experimental OA,38 suggesting a
complementary approach with drugs that inhibit iNOS may
be useful. Our study confirms an inhibitory effect of rhein on
the NO° production induced by IL-1. This effect occurs in
a dose-dependent manner and at the therapeutic concen-
tration for OA patients. Rhein has a similar effect on nitrite
(the end-metabolite of NO°) and nitrosothiol production.
When rhein is introduced 18 h after IL-1 at a therapeutic
concentration, it inhibits about 50% of nitrosothiol produc-
tion, suggesting that this molecule could have a strong
effect on damages produced by acute, subacute or chronic
inflammatory states. Our results are in accordance with
those of Pelletier et al.,25 who showed on a similar cellular
model that diacerein and its active metabolite rhein partially
inhibited the production of iNOS mRNA induced by IL-1.
Few therapeutic drugs have the ability to inhibit NO°
production. An inhibitory effect has been reported for tetra-
cyclines,39 aspirin,40 and partially for corticoids41 but most
NSAIDs do not inhibit the NO° production induced by IL-1
in cultured chondrocytes.42 Our results confirm these
observations since we did not observe any effect of
diclofenac on nitrosothiol or nitrite production. We did find
an effect of cortisol. However, effects of corticoids on the
inducible NO synthase are still not well known. Our results
are similar to those reported by Grabowski et al.43 The
exact mechanism by which rhein acts to regulate NO°
production is not well known. It was previously shown that
rhein can inhibit the synthesis of IL-1 on human OA
synovium and reduce the number of chondrocyte IL-1
receptors,44 but rhein can also directly inhibit iNOS gene
expression.40 However, the inhibitory effects of rhein seem
to be more efficient when the drug is co-incubated with
IL-1 than when it is introduced after a previous stimulation
by IL-1.
In conclusion, this study demonstrates that human OA
chondrocytes, after IL-1 stimulation, are able to produce
high quantities of nitrosothiols, a bioactive form of NO°.These results illustrate the need to measure nitrosothiol as
well as nitrite production, since pharmacological molecules
can modify the cellular redox balance and liberate NO from
nitrosothiols or divert the NO pathway. Rhein had a signifi-
cant inhibitory effect on NO° production by OA chondro-
cytes. In view of pharmacological properties, these results
add some more information to the body of evidence
obtained previously with diacerein and rhein on in vitro
and animal models. Futher studies on joint structure
modifications are proceeding.References
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